Visit other SMART + STRONG sites:
POZ • REAL HEALTH • TU SALUD
Subscribe to:
• E-newsletters
• POZ magazine
POZ Personals
Sign In / Join		 Username:
 Password:
Back to home » Top Stories » ICAAC/IDSA 2008
ICAAC/IDSA 2008 48th ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008

HIV News at ICAAC/IDSA - Part 2

November 4, 2008

At the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA), Tim Horn speaks with Roy M. Gulick, MD, MPH, a professor of medicine at the Weill College of Medicine of Cornell University and the director of the Cornell Clinical Trials Unit in New York. In this second of a two-part interview, Dr. Gulick reviews some of the noteworthy HIV presentation at ICAAC/IDSA, including new data from studies of antiretrovirals for first-time treatment takers and treatment veterans.

 


14 1/2 minutes. Transcript coming soon! To view Part 1, click here.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       

More from ICAAC/IDSA 2008

Starting and Switching Treatment

November 4, 2008
HIV News at ICAAC/IDSA - Part 1
HIV News at ICAAC/IDSA - Part 2
November 3, 2008
Truvada vs. Epzicom: The Debate Goes On
October 30, 2008
Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studies
October 28, 2008
Greater HIV Response to Prezista vs. Kaletra for First-Timers Over 96 Weeks
Higher Response Rate with Norvir-Boosted Reyataz vs. Kaletra as First-Line Therapy
October 27, 2008
Isentress Comparable to Sustiva for First-Time Treatment
Selzentry Reanalysis Shows Potential as First-Line Treatment
Should ARV Treatment Be Started When CD4s Fall Below 500?

HIV/AIDS Complications

November 4, 2008
Drug-Resistant Staph: Growing Concern Among People With HIV
High Number of Pulmonary Hypertension Cases in Naval HIV Cohort Study
Drug-Resistant Staph and HIV - Part 1
Drug-Resistant Staph and HIV - Part 2

Experimental HIV Drugs

October 28, 2008
PRO 140 Has Long-Lasting Activity Against HIV
New NNRTI Called RDEA806 Shows Promise

HIV Transmission and Prevention

October 29, 2008
Has HIV Evolved to Become More Dangerous?


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy